Position in JBIO
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$8,928,746
-$4,760,425 QoQ
Shares Held
635,498
-28.4% QoQ
Ownership
0.999%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2022
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in JBIO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Driehaus Capital Management LLC holds $3,602,052,293 across 59 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | DFTX |
Definium Therapeutics, Inc.
|
6,845,276 | $322,001,783 | |
| 2 | PRAX |
Praxis Precision Medicines, Inc.
|
959,048 | $321,079,679 | |
| 3 | XENE |
Xenon Pharmaceuticals Inc.
|
4,418,557 | $266,704,100 | |
| 4 | SYRE |
Spyre Therapeutics, Inc.
|
2,799,166 | $248,509,957 | |
| 5 | CRNX |
Crinetics Pharmaceuticals, Inc.
|
6,463,551 | $241,866,078 | |
| 6 | APGE |
Apogee Therapeutics, Inc.
|
1,740,101 | $230,963,605 | |
| 7 | EWTX |
Edgewise Therapeutics, Inc.
|
4,728,623 | $192,123,952 | |
| 8 | SEPN |
Septerna, Inc.
|
4,433,058 | $148,463,112 |
All Filings in JBIO
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $8,928,746 | 635,498 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $13,689,171 | 887,179 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $10,837,536 | 1,255,798 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $12,545,422 | 1,255,798 | Shares | Sole | 2025-08-14 | |
| 2024-03-31 AVTE | — | 794,992 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 AVTE | — | 1,058,209 | Shares | Sole | 2024-02-14 | |
| 2023-09-30 AVTE | — | 1,187,618 | Shares | Sole | 2023-11-14 | |
| 2023-06-30 AVTE | — | 1,194,091 | Shares | Sole | 2023-08-14 | |
| 2022-09-30 AVTE | — | 46,864 | Shares | Sole | 2022-11-14 | |
| No filing history on record for this holder in this stock. | ||||||